Thus, our study indicate that VPRBP inhibition produces two seemingly opposing effects on tumor development by suppressing tumor cell growth by activation of p53 but also allowing tumor cells to evade immunosurveillance through increased PD-L1 levels. This evidence concerns the gene TP53 and neoplasm.